Advertisement
U.S. markets close in 2 hours 37 minutes
Advertisement

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
34.96+1.50 (+4.48%)
As of 01:22PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close33.46
Open33.48
Bid34.93 x 900
Ask34.97 x 1200
Day's Range33.36 - 35.12
52 Week Range25.98 - 47.49
Volume725,432
Avg. Volume1,490,331
Market Cap3.428B
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-5.55
Earnings DateFeb 28, 2024 - Mar 04, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cytokinetics, Incorporated
    CYTK: Raising target price to $26.00CYTOKINETICS INC has an Investment Rating of SELL; a target price of $26.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND

    As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints Trial Discontinued in March 2023 Due to Futility Following Second Planned Interim Analysis Survey Reveals Site Personnel and Patients Have Favorable View of Trial Features to Reduce Burden of Participation SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results of COURAGE-AL

  • GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate of 25,350 shares of common stock to two new employees, whose employment commenced in November 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.48 per share, which is equal to the closing price of the Company’s common stock o

  • GlobeNewswire

    Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

    Results from COURAGE-ALS to Be Presented on December 7, 2023SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34th International Symposium on ALS/MND taking place in Basel, Switzerland and online from December 6, 2023 - December 8, 2023. Oral Presentations Title: Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALSPresenter: Stacy Rudnicki, M.D., V